Inhibitor of novel cancer target, LPAAT-beta, demonstrates selective anti-cancer effects

Frankfurt, Germany--In a plenary session at the Symposium on Molecular Targets and Cancer Therapeutics, Dr Jack W. Singer, M.D. and Research Program Chairman of Cell Therapeutics, Inc. (CTI) today (Thursday 21 November) presented data from preclinical studies on a novel cancer target LPAAT-beta[1] in cultured cells and in preliminary animal models.

Through preclinical studies, CTI scientists found that LPAAT-beta is highly expressed in cancers of the lung, ovary, prostate, bladder, cervix and brain but is minimally expressed in most normal tissues. When LPAAT-b was over expressed in cell lines, they became more tumorigenic and this change was reversed when the over-expressed gene was removed. When LPAATb expression was decreased in tumor cells by a genetic technique known as RNAi, their proliferation decreased. CTI scientists also developed small molecule inhibitors specific to LPAAT-b and these compounds induce apoptosis (cell death) in a wide variety of tumor cell lines. When nude mice bearing HT-29 colon cancer were treated with the compound, it delayed tumor growth significantly without producing toxicities. Similar results were achieved with related compounds in mice with Lewis lung cancers or NCI-H460 human lung cancers.

"These data affirm what we had previously noted in our initial studies that the enzyme LPAAT-b produces a cofactor for signalling pathways that may be essential to cancer cell growth and viability and the inhibition of this enzyme causes cancer cells to die," Dr Singer told a news briefing today (Thursday 21 November) at the EORTC-NCI-AACR[2] Symposium on Molecular Targets and Cancer Therapeutics.

He added: "The experiments in animal models show that the small molecule LPAAT-b inhibitors can effectively kill tumor cells without having pronounced effects on normal cells."


Contact: Margaret Willson
European Organisation for Research and Treatment of Cancer

Page: 1

Related biology news :

1. Natures own medicine for vision loss: Inhibitor of angiogenesis found by biologists at The Scripps Research Institute
2. Research Findings Suggest Potent, Broad-Spectrum Antiviral Activity For Vertexs Investigational IMPDH Inhibitor VX-497
3. Use Of Protease Inhibitors For HIV Associated With Dramatic Rise In Oral Warts
4. How Super Are The "Super Aspirins"? -- New COX-2 Inhibitors May Elevate Cardiovascular Risk
5. Cholesterol Inhibitors In Garlic Identified
6. Phase III Results Suggest Potent Antiviral Activity For Vertex And Glaxo Wellcomes Second-Generation HIV Protease Inhibitor Agenerase TM
7. New Class Of Protease Inhibitors May Be Effective In Treating One Of Latin Americas Most Devastating Diseases
8. HIV-Positive Injection Drug Users Often Dont Receive Protease Inhibitors And May Not Be Aware Of The Drug
9. Inhibitor Shows Potential To Protect Infant Brain
10. A novel, safer strategy for regulating gene expression
11. European common frog found to use novel mating strategy

Post Your Comments:

(Date:7/18/2020)... TORONTO (PRWEB) , ... July 17, 2020 , ... Commercial ... hangs on pharma’s ability to discover a COVID cure or vaccine, the global economic ... competitive and price pressure is not going away and capturing full value from every ...
(Date:7/2/2020)... (PRWEB) , ... July 02, ... ... Biology Systems, B.V. (MBS) has announced a publication detailing the use of ... reverse transcription polymerase chain reaction (RT-PCR) in 16 minutes. The article, titled ...
(Date:6/25/2020)... ... June 24, 2020 , ... ... software-driven clinical data services that accelerate drug development, is collaborating with Karyopharm Therapeutics ... inhibitor, in hospitalized patients with severe COVID-19. This is the first study of ...
Breaking Biology News(10 mins):
(Date:8/31/2020)... ... August 29, 2020 , ... DuPont Nutrition & ... Wuxi, China. The new plant operation will provide the local animal production industry ... , “This facility will improve the flexibility of our offerings to the Chinese ...
(Date:8/12/2020)... ... August 11, 2020 , ... The ... the Facioscapulohumeral Muscular Dystrophy Clinical Trial Research Network (FSHD CTRN), with ... network is a consortium of academic research centers in the United States and ...
(Date:8/7/2020)... ... August 06, 2020 , ... VGXI, ... it has closed on the purchase of greenfield for a new, expanded manufacturing ... includes over 21 acres in the initial acquisition, with an option to purchase ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is now ... With 50 million stem cells total, patients may choose which extremities they would like ... arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is obtained ...
Breaking Biology Technology:
Cached News: